At Week 8 , the HAM-A and SDS total scores , CGI and Q-LES-Q scores , and response and remission rates demonstrated similar improvement for vortioxetine and venlafaxine XR , with remission rates ( MADRS 10 ) of 43.1 % ( vortioxetine ) versus 41.4 % ( venlafaxine XR ) ( LOCF ) .